Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists
- PMID: 21388453
- DOI: 10.1111/j.1468-3083.2011.03990.x
Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists
Abstract
Background: There is a high level of heterogeneity regarding the practical use of conventional systemic treatment in psoriasis.
Objectives: The aim of this study was to develop evidence-based recommendations for the use of traditional systemic treatments in psoriasis in daily clinical practice: methotrexate (MTX), cyclosporin and retinoids.
Methods: A scientific committee selected clinically relevant questions concerning the use of MTX, cyclosporin and retinoids in psoriasis. This selection was made using the Delphi method. A systematic literature search was performed in Medline, Embase and the Cochrane Library. The articles selected for analysis were reviewed and the level of evidence was appraised according to the Oxford Levels of Evidence. An Expert consensus meeting took place in June 2010, including 66 dermatologists. Recommendations for daily use of psoriasis systemic treatments were made during interactive workshops where the evidence was reviewed. Agreement among participants and the impact of the recommendations on clinical practice were systematically assessed using voting procedure in a plenary session.
Results: A total of 2800 references were identified, among which 122 articles were included in the systematic reviews. Three key recommendations on the use of MTX in psoriasis were formulated, including optimal dosage and route, use of folic acid, risk factors for liver fibrosis and monitoring of hepatotoxicity. The recommendations for cyclosporin in psoriasis focused on the modalities of cyclosporin prescription: dosage, scheme of treatment, optimal duration of treatment, renal toxicity monitoring and evidence for use of cyclosporin in non-plaque psoriasis (erythrodermic, pustular and ungueal). Recommendations were also made concerning the efficacy and safety of retinoids (mainly acitretin) in plaque and non-plaque psoriasis.
Conclusions: These recommendations for the use of traditional systemic therapies in psoriasis are evidence based and supported by a panel of dermatologists. The next step will be to disseminate these recommendations and assess the agreement of physicians who were not involved in generating the recommendations.
© 2011 The Authors. JEADV © 2011 European Academy of Dermatology and Venereology.
Similar articles
-
Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists.J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:1-10. doi: 10.1111/j.1468-3083.2012.04518.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22512675
-
Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion.J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:2-11. doi: 10.1111/jdv.12162. J Eur Acad Dermatol Venereol. 2013. PMID: 23845148
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:2-9. doi: 10.1111/j.1468-3083.2009.03561.x. J Eur Acad Dermatol Venereol. 2010. PMID: 20443994
Cited by
-
[Methotrexate and psoriasis: about 46 cases].Pan Afr Med J. 2014 Sep 25;19:84. doi: 10.11604/pamj.2014.19.84.5165. eCollection 2014. Pan Afr Med J. 2014. PMID: 25709742 Free PMC article. French.
-
Pros and cons of using systemic acitretin in the paediatric population.Postepy Dermatol Alergol. 2022 Feb;39(1):34-38. doi: 10.5114/ada.2020.98558. Epub 2020 Sep 1. Postepy Dermatol Alergol. 2022. PMID: 35369612 Free PMC article. Review.
-
Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.Indian Dermatol Online J. 2020 Jan 13;11(1):51-57. doi: 10.4103/idoj.IDOJ_169_19. eCollection 2020 Jan-Feb. Indian Dermatol Online J. 2020. PMID: 32055509 Free PMC article.
-
Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.Pharmacoeconomics. 2015 Feb;33(2):163-77. doi: 10.1007/s40273-014-0226-y. Pharmacoeconomics. 2015. PMID: 25526841
-
Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study.Indian J Dermatol. 2023 Nov-Dec;68(6):669-673. doi: 10.4103/ijd.ijd_551_23. Epub 2024 Jan 9. Indian J Dermatol. 2023. PMID: 38371546 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical